| Project/Area Number |
25861463
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
LI Bin 東北大学, 東北メディカル・メガバンク機構, 研究支援者 (20566814)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 子宮筋腫 / SERM / ELT-3細胞 / ヒト子宮筋腫モデルマウス / 子宮筋腫モデルマウス |
|---|
| Outline of Final Research Achievements |
SS5020, a new benzopyran antiestrogen, has anti-breast cancer potential in rats and mice model. In this study, we investigated the inhibitory effect of SS5020 on uterine leiomyomas.
In vitro study, SS5020 inhibited ELT-3 cell proliferation. In vivo study, human leiomyoma tumor tissues were collected from female Japanese patients at the time of hysterectomy and implanted into immunodeficient mouse. Mice were administered orally with SS5020. The results showed that SS5020 administration inhibited the enlargement of the tumor, caused the inhibitory effect of cellular proliferation and ER, PR expression levels. Furthermore, SS5020 increased TUNEL positive cells. However, the expression levels of smooth muscle actin (SMA) and collagen components exhibited no significant changed. These experimental findings showed that SS5020 inhibited uterine leiomyoma cells proliferation. However, the inhibitory effect was not as strong as to affect the expression levels of SMA and collagen components.
|
